Phase 1 clinical trial demonstrates efficacy and safety of VG161 in advanced hepatocellular carcinoma, suggesting a new treatment option.
The study titled “Oncolytic virus VG161 in refractory hepatocellular carcinoma” presents a promising advancement in third-line therapy for advanced hepatocellular carcinoma (HCC). VG161, derived from an oncolytic herpes simplex virus, is engineered to express interleukin (IL)-12, IL-15, IL-15R, and a fusion protein that blocks the programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) pathway. In the multicenter phase 1 clinical trial, VG161 exhibited both strong efficacy and safety. This paper summarizes the study’s findings, discusses potential limitations, and proposes directions for future research.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: